Supernus Pharmaceuticals Q1 2026: Record Revenue & Pipeline Progress

Supernus Pharmaceuticals kicked off 2026 with a strong start, reporting a 39% increase in total revenue to $207.7 million in Q1. Their growth products drove this surge, with combined revenues jumping 56% year over year and adjusted operating earnings climbing 11%. Onepco bounced back strongly after supply hiccups, with net sales hitting $8.4 million and March prescriptions topping 463, surpassing pre-constraint levels. Zirzuve collaboration revenue came in at $27.6 million, with U.S. sales doubling year over year. Kellis ADHD med saw net sales rise 20% to $78 million, while Gocovri grew 15% to $35.2 million. Analysts and execs highlighted solid momentum across the board, with Kellis adult prescriptions up 27% and Onepco patient enrollment topping 2,200 forms since launch. Pipeline progress includes ongoing phase two trials for SPN-820 in depression and SPN-817 for seizures, plus a phase one start for SPN-443 in ADHD this year. Supernus aims for a second Onepco supplier filing in Q3 and cash sits at $384 million, debt-free for more deals. Guidance holds firm at $840 to $870 million in full-year revenue and non-GAAP earnings of $140 to $170 million, setting up Supernus for sustained growth in CNS and beyond. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/5e992c9814067f63